RERG Polyclonal antibody

• Home
• Products
• Primary Antibodies
• RERG Polyclonal antibody (10687-1-AP)

• Featured Product
• KD/KO Validated

RERG Polyclonal Antibody for WB, ELISA

Cat No. 10687-1-AP Copied!

Publications (6)

Download datasheet

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse

Applications

WB, IHC, IF, ELISA

Synonyms

EC:3.6.5.2, Ras-related and estrogen-regulated growth inhibitor, RERC

• 

  WB analysis of MCF-7 using 10687-1-AP

  WB result of RERG antibody (10687-1-AP; 1:1000; incubated at room temperature for 1.5 hours) with sh-Control and sh-RERG transfected MCF-7 cells.

  This validation data has been generated in-house and reviewed by Proteintech scientists. Find out more on our antibody validation policy
• 

  WB analysis using 10687-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 10687-1-AP (RERG antibody) at dilution of 1:3000 incubated at room temperature for 1.5 hours.

  This validation data has been generated in-house and reviewed by Proteintech scientists. Find out more on our antibody validation policy
• 

  WB analysis of NIH/3T3 using 10687-1-AP

  NIH/3T3 cells were subjected to SDS PAGE followed by western blot with 10687-1-AP (RERG antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

  This validation data has been generated in-house and reviewed by Proteintech scientists. Find out more on our antibody validation policy
• 

  WB analysis of MCF-7 using 10687-1-AP

  MCF7 cells were subjected to SDS PAGE followed by western blot with 10687-1-AP (RERG antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

  This validation data has been generated in-house and reviewed by Proteintech scientists. Find out more on our antibody validation policy

Able AI

What's the best dilution for RERG in ?

Chat with Able

---

Tested Applications

• Positive WB detected in: NIH/3T3 cells, MCF-7 cells

Recommended dilution

• Western Blot (WB): WB : 1:1000-1:6000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

10687-1-AP targets RERG in WB, IHC, IF, ELISA applications and shows reactivity with human, mouse samples.

• Tested Reactivity: human, mouse
• Cited Reactivity: human
• Host / Isotype: Rabbit / IgG
• Class: Polyclonal
• Type: Antibody
• Immunogen:

  CatNo: Ag1041

  Product name: Recombinant human RERG protein

  Source: e coli.-derived, PGEX-4T

  Tag: GST

  Domain: 1-199 aa of BC007997

  Sequence: MAKSAEVKLAIFGRAGVGKSALVVRFLTKRFIWEYDPTLESTYRHQATIDDEVVSMEILDTAGQEDTIQREGHMRWGEGFVLVYDITDRGSFEEVLPLKNILDEIKKPKNVTLILVGNKADLDHSRQVSTEEGEKLATELACAFYECSACTGEGNITEIFYELCREVRRRRMVQGKTRRRSSTTHVKQAINKMLTKISS

• Full Name: RAS-like, estrogen-regulated, growth inhibitor
• Calculated Molecular Weight: 23 kDa
• Observed Molecular Weight: 23-26 kDa
• GenBank Accession Number: BC007997
• Gene Symbol: RERG
• Gene ID (NCBI): 85004
• RRID: AB_2253772
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Antigen affinity purification
• UNIPROT ID: Q96A58
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol, pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

RERG (Ras-related and estrogen-regulated growth inhibitor), a gene that encodes a small GTP binding and hydrolyzing protein (GTPase) of the Ras superfamily, is a novel gene that was first reported in breast cancer. RERG gene expression is stimulated by the estrogen receptor alpha (ERalpha), and RERG gene expression is absent in ER-negative breast cancer. RERG can bind and hydrolyze GTP as a GTP/GDP molecular switch, and RERG has been shown to possess growth inhibitory activity in breast cancer cells.

Publications

What published studies show

The RERG antibody (Cat# 10687-1-AP) has 6 total citations published in Oncology Reports, FASEB Journal, Frontiers in Medicine, Frontiers in Oncology, Breast Cancer Research and Treatment, and Oncotarget. The research fields span prostate cancer progression, breast cancer subtype classification, neuroendocrine differentiation, ERβ signaling, microRNA regulation, and tumor cell invasion, with applications primarily in WB, IHC, and IF.

Automatically generated from the 6 publication citations by Able AI.

• Human
• Mouse
• Rat
• Monkey
• Pig

Species	Application	Title
		Oncol Rep; ERK5‑regulated RERG expression promotes cancer progression in prostatic carcinoma.; Authors - Ying Xiong
human	WB,IHC	FASEB J; Tumor-Associated Macrophage Exosomal miR-142-5p Drives Prostate Cancer Neuroendocrine Differentiation via RERG/Ras/ERK Axis.; Authors - Bo-Han Lin
human	IHC	Front Med (Lausanne); Missing link between tissue specific expressing pattern of ERβ and the clinical manifestations in LGBLEL; Authors - Xujuan Zhang
human	WB,IF	Front Oncol; The NFAT3/RERG Complex in Luminal Breast Cancers Is Required to Inhibit Cell Invasion and May Be Correlated With an Absence of Axillary Lymph Nodes Colonization.; Authors - Lucie Coillard ; KD Validated
human	IHC	Breast Cancer Res Treat; RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.; Authors - Habashy Hany Onsy HO
human	WB,IHC	Oncotarget; MicroRNA-382-5p aggravates breast cancer progression by regulating the RERG/Ras/ERK signaling axis.; Authors - Jar-Yi Ho